Search for substrate-based inhibitors fitting the S2′ space of malarial aspartic protease plasmepsin II

Journal of Peptide Science

Volumn 10, Issue 11, 2004, Pages 641-647

  Kiso, Aiko ^a   Hidaka, Koushi ^a   Kimura, Tooru ^a   Hayashi, Yoshio ^a   Nezami, Azin ^b   Freire, Ernesto ^b   Kiso, Yoshiaki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allophenylnorstatine; Antimalarial drug; Aspartic protease inhibitor; Plasmepsin; Transition state mimic

Indexed keywords

ANTIMALARIAL AGENT; ASPARTIC PROTEINASE; DIPEPTIDE; HYDROXYL GROUP; KNI 727; KNI 764; KNI 840; PLASMEPSIN II; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MALARIA FALCIPARUM; NONHUMAN; PHASE TRANSITION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; STARVATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ASPARTIC ENDOPEPTIDASES; BINDING SITES; ENZYME INHIBITORS; MOLECULAR MIMICRY; OLIGOPEPTIDES; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP;

PLASMODIUM FALCIPARUM;

EID: 8644243887     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.609     Document Type: Article

References (20)

1. Banerjee R, Goldberg DE. In Antimalarial Chemotherapy, Rosenthal PJ (ed.). Humana Press: Totawa, NJ, 2001; 43-63.
2. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. Natl Acad. Sci. USA 2002; 99: 990-995.
3. Cooms GH, Goldberg DE, Klemba M, Berry C, Kay J, Mottram JC. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 2001; 17: 532-537.
4. Francis SE, Sullivan DJ Jr, Goldberg DE. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu. Rev. Microbiol. 1997; 51: 97-123.
5. Nezami A, Luque I, Kimura T, Kiso Y, Freire E. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target. Biochemistry 2002; 41: 2273-2280.
6. Nezami A, Kimura T, Hidaka K, Kiso A, Liu J, Kiso Y, Goldberg DE, Freire E. High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 2003; 42: 8459-8464.
7. Francis SE, Gluzman IY, Oksman A, Knickerbocker A, Mueller R, Bryant ML, Sherman DR, Russell DG, Goldberg DE. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J. 1994; 13: 306-317.
8. Silva AM, Lee AY, Gulnik SV, Majer P, Collins J, Bhat TN, Collins PJ, Cachau RE, Lurer KE, Gluzman IY, Francis SE, Oksman A, Goldberg DE, Erickson JW. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc. Natl Acad. Sci. USA 1996; 93: 10034-10039.
9. Moon RP, Tyas L, Certa U, Rupp K, Bur D, Jacquet C, Matile H, Loetscher H, Grueninger-Leitch F, Kay J, Dunn BM, Berry C, Ridley RG. Expression and characterization of plasmepsin I from Plasmodium falciparum. Eur. J. Biochem. 1997; 244: 552-560.
10. Carroll CD, Johnson TO, Tao S, Lauri G, Orlowski M, Gluzman IY, Goldberg DE, Dolle RE. Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D. Bioorg. Med. Chem. Lett. 1998; 8: 3203-3206.
11. Haque TS, Skillman AG, Lee CE, Habashita H, Gluzman IY, Ewing TJA, Goldberg DE, Kuntz ID, Ellman JA. Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. J. Med. Chem. 1999; 42: 1428-1440.
12. Ersmark K, Feierberg I, Bjelic S, Hamelink E, Hackett F, Blackman MJ, Hulten J, Samuelsson B, Qvist J, Hallberg A. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. J. Med. Chem. 2004; 47: 110-122.
13. Mimoto T, Imai J, Tanaka S, Hattori N, Kisanuki S, Akaji K, Kiso Y. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem. Pharm. Bull 1991; 39: 3088-3090.
14. Kiso Y, Matsumoto H, Mizumoto S, Kimura T, Fujiwara Y, Akaji K. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Biopolymer 1999; 51: 59-68.
15. Kiso Y, Yamaguchi S, Matsumoto H, Mimoto T, Kato R, Nojima S, Takaku H, Fukazawa T, Kimura T, Akaji K. KNI-577, a potent small-sized HIV protease inhibitor based on the dipeptide containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Arch. Pharm. Pharm. Med. Chem. 1998; 331: 87-89.
16. Matsumoto H, Kimura T, Hamawaki T, Kumagai A, Goto T, Sano K, Hayashi Y, Kiso Y. Design, synthesis, and biological evaluation of anti-HIV double-drug: conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor through spontaneously cleavable linkers. Bioorg. Med. Chem. 2001; 9: 1589-1600.
17. Mimoto T, Kato R, Takaku H, Nojima S, Terasawa K, Misawa S, Fukazawa T, Ueno T, Sato H, Shintani M, Kiso Y, Hayashi H. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. J. Med. Chem. 1999; 42: 1789-1802.
18. Kiso Y. Design and synthesis of a covalently linked HIV-1 protease dimer analog and peptidomimetic inhibitors. J. Synth. Org. Chem., Jpn 1998; 56: 896-907.
19. Gluzman IY, Francis SE, Oksman A, Smith CE, Duffin KL, Goldberg DE. Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. J. Clin. Invest. 1994; 93: 1602-1608.
20. KNI-10 006 with Apns-Dmt scaffold is highlighted in Editors' choice. Science 2003; 301: 143.